Experimental pancreatic tetrapeptide · Fact sheet
Pancragen
Pancragen is a tetrapeptide investigated in pancreatic-cell, animal and small older-adult metabolic reports. These findings do not establish pancreatic regeneration or a reliable diabetes treatment.
What is Pancragen?
The research concerns a synthetic tetrapeptide and endocrine-pancreatic biology.
Animal glucose regulation and cell-differentiation markers are different from durable clinical control or fewer diabetes complications.
Benefits & claims
Interest centers on metabolic function, aging and cellular function. Biological activity does not itself establish a clinical treatment.
What the evidence supports
- Cell studies reported changes in pancreatic differentiation factors.
- The monkey study measured glucose, insulin and C-peptide after short treatment.
- The limited human report needs rigorous controlled replication before claiming effective diabetes treatment.
Research areas
- Experimental tissue and cellular responses
- Formulation-specific outcomes
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Pancragen. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- The research concerns a synthetic tetrapeptide and endocrine-pancreatic biology.
Formulation differences
- Animal glucose regulation and cell-differentiation markers are different from durable clinical control or fewer diabetes complications.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Controlled human clinical outcomes for the exact substance
- Human exposure, pharmacokinetics and repeated-use safety
- Independent replication and formulation equivalence
Side effects & risks
- Glucose-related activity requires direct evaluation of hypoglycemia and interactions with diabetes medicines.
- Small, short and incompletely described studies do not establish long-term pancreatic or systemic safety.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceA small report compared older people with and without diabetes and described metabolic changes, with limited accessible design detail. Supporting work includes cell cultures and nine old rhesus monkeys.
Studies
Pancreatic-cell differentiation study.
Older-adult metabolic report; limited indexed design detail.
Nine older female rhesus monkeys; short metabolic experiment.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
Pancragen has no FDA-approved therapeutic product. The cited experiments or cosmetic uses do not establish an approved human treatment.
No FDA-approved product for this entry
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Controlled human clinical outcomes for the exact substance
- Human exposure, pharmacokinetics and repeated-use safety
- Independent replication and formulation equivalence
Summary
The limited human report needs rigorous controlled replication before claiming effective diabetes treatment.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedEffects of pancragen on the differentiation of pancreatic cells during their ageing.
Pancreatic-cell differentiation study.
- pubmedProspects of using pancragen for correction of metabolic disorders in elderly people.
Older-adult metabolic report; limited indexed design detail.
- pubmed[Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys].
Nine older female rhesus monkeys; short metabolic experiment.